Royalty Pharma
Royalty Pharma is the leading buyer of biopharmaceutical royalties and a primary funder of innovation across the life sciences industry. The company acquires interests in the top-line sales of approved and development-stage therapies, providing non-dilutive capital to academic institutions, non-profits, and biotechnology companies. Its business model offers investors diversified exposure to high-growth blockbuster drugs while mitigating the operational risks and costs associated with traditional drug development and commercialization.
Financials
Based on Q1 2026 filing
Business Segments
Marketed Royalties
primaryRoyalties on biopharmaceutical products that have received regulatory approval and are being commercialized by global pharmaceutical partners. These assets provide immediate cash flow based on top-line sales across various therapeutic areas.
Trikafta, Trelegy, Tysabri, Evrysdi, Xtandi, Tremfya, Imbruvica, Promacta, Voranigo, Cabometyx, Spinraza, Trodelvy, Erleada, Imdelltra, Amvuttra
Global Pharmaceutical Companies, Mid-cap Biotechnology Companies, Academic Institutions, Research Hospitals
Development-Stage Royalties & Funding
moderateInvestments in product candidates currently in clinical trials that have not yet received regulatory approval. This segment includes synthetic royalties and other funding modalities like launch capital and development co-funding.
Ampreloxetine, Daraxonrasib, Deucrictibant, Frexalimab, Litifilimab, Olpasiran, Pelabresib, Seltorexant, TEV-'749, Tividenofusp alfa
Biotechnology Companies, Pharmaceutical Marketers
Segment Financials
Trelegy — Milestone payable
View metricPhase 3, TEV-408 — Research and development commitment
View metricPhase 2b, TEV-408 — Research and development commitment
View metricPhase 2b, TEV-408 — Research and development funding expense
View metricBusiness Overview
Competitive Position
The company is the largest player in the biopharmaceutical royalty market, holding a significant market share of large-scale transactions compared to its nearest competitors.
Geographies
Global, United States, Europe, China
Customer Segments
Biopharmaceutical Companies, Academic Institutions, Non-profit Research Organizations
Upstream Dependencies
Academic research institutions, Biotechnology R&D, Clinical trial results, Regulatory approval bodies (FDA/EMA)
Downstream Customers
Global pharmaceutical marketers, Healthcare payors, Patients
Competitors & Partners
Partners
Vertex Pharmaceuticals
VRTX
Marketer of the cystic fibrosis franchise
GlaxoSmithKline
GSK
Marketer of Trelegy
Biogen
BIIB
Marketer of Tysabri and Spinraza; R&D funding partner
Pfizer
PFE
Marketer of Xtandi
Johnson & Johnson
JNJ
Marketer of Tremfya, Imbruvica, and Erleada
AbbVie
ABBV
Marketer of Imbruvica
Gilead Sciences
GILD
Marketer of Trodelvy
Amgen
AMGN
Marketer of Imdelltra and Olpasiran
Alnylam Pharmaceuticals
ALNY
Marketer of Amvuttra
Novartis
NVS
Marketer of Promacta and Pelabresib
Cytokinetics
CYTK
Development and commercial launch funding partner
Teva Pharmaceutical Industries Limited
TEVA
Development co-funding partner
Revolution Medicines, Inc.
RVMD
Funding arrangement partner for daraxonrasib
Blackstone
BX
Third-party seller of royalty interests
Subsidiaries
Royalty Pharma Holdings Ltd
Principal holding company subsidiary
Royalty Pharma, LLC
Operating subsidiary following the internalization of the manager
Royalty Pharma FAQ
Common questions about Royalty Pharma
Royalty Pharma is the leading buyer of biopharmaceutical royalties and a primary funder of innovation across the life sciences industry. The company acquires interests in the top-line sales of approved and development-stage therapies, providing non-dilutive capital to academic institutions, non-profits, and biotechnology companies. Its business model offers investors diversified exposure to high-growth blockbuster drugs while mitigating the operational risks and costs associated with traditional drug development and commercialization.
Royalty Pharma (RPRX) has a market capitalization of $23.1B and trades on NASDAQ.
Royalty Pharma generated $2.4B in trailing twelve-month revenue with net income of $827.3M, representing a net margin of 33.9%. These figures are based on the Q1 2026 filing.
Royalty Pharma's key competitors include Roivant Sciences Ltd. Common Shares, Alnylam Pharmaceuticals, Inc., Viatris Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Royalty Pharma has approximately 89 employees.